Table 1

Summary of main urinary markers

Markers

Overall sensitivity, %

Overall specificity, %

Sensitivity for high-grade tumors, %

Point-of-care test

Interferenceb

Comments


Aneuploidy detection kitc

30 to 72

63 to 95

66 to 70

No

No

Expensive and laborious


Microsatellite analysis

58

73

90

No

No

Expensive and laborious


Gene microarray

80 to 90

62 to 65

80

No

No

Expensive and laborious


Monoclonal antibodiesd

76 to 85

63 to 75

67 to 92

No

Yes

Good sensitivity in low-grade tumors, affected by BCG


NMP 22

49 to 68

85.8 to 87.5

75 to 83

Yes

Yes

Low sensitivity, affected by benign conditions


Physician-use BTA immunoassaye

57 to 83

68 to 85.7

61.5

Yes

Yes

Low sensitivity, affected by benign conditions and BCG


Quantitative laboratory BTA immunoassayf

53 to 91

28 to 83

77

No

Yes

Low sensitivity, affected by benign conditions and BCG


Cytokeratins

12 to 85

75 to 97

33 to 82

No

Yes

Low sensitivity, affected by benign conditions and BCG


Survivin

53 to 90

88 to 100

50

No

No

Low sensitivity, expensive and laborious


Abbreviations: BCG, bacille Calmette-Guérin; BTA, bladder tumor-associated antigen; NMP, nuclear matrix protein

aAdapted from Expert Review of Anticancer Therapy, June 2010, Vol. 10, No. 6, Pages 787-790 with permission of Expert Reviews Ltd.

bBy BCG instillations and other bladder conditions.

cUroVysion®; Abbott Molecular Inc , Des Plaines, IL, USA.

dImmunocyt/uCyt+™; DiagnoCure Inc., Québec, Canada.

eBTA stat®; Polymedco Inc., Cortlandt Manor, NY, USA.

fBTA TRAK™; Polymedco Inc.

Cheung et al. BMC Medicine 2013 11:13   doi:10.1186/1741-7015-11-13

Open Data